Clinical expression of leflunomide-induced pneumonitis

Rheumatology

Volumn 48, Issue 9, 2009, Pages 1065-1068

  Chikura, Batsi ^a   Lane, Steven ^b   Dawson, Julie K ^c  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c St Helens Hospital   (United Kingdom)

Author keywords

Delayed hypersensitivity; Hypersensitivity pneumonitis; Interstitial lung disease; Leflunomide induced pneumonitis

Indexed keywords

ANTIBIOTIC AGENT; COLESTYRAMINE; LEFLUNOMIDE; METHOTREXATE; STEROID; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LEFLUNOMIDE INDUCED PNEUMONITIS; LOADING DRUG DOSE; LUNG ALVEOLUS; MALE; MORTALITY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; RADIOGRAPHY; RETROSPECTIVE STUDY; REVIEW;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LUNG DISEASES, INTERSTITIAL; MALE; METHOTREXATE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349783402     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep050     Document Type: Article

References (38)

1. Chong AS, Huang W, Liu W et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999;68:100-9.
2. Cohen S, Cannon GW, Schiff M et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984-92.
3. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
4. Nash P, Thaci D, Behrens F, Falk F, Kaltwasser JP. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 2006;212:238-49.
5. Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008;58:403-6.
6. Silverman E, Mouy R, Spiegel L et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66.
7. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:43-8.
8. Holtmann MH, Gerts AL, Weinman A, Galle PR, Neurath MF. Treatment of Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety. Dig Dis Sci 2008;53:1025-32.
9. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004;43:315-20.
10. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004;363:461.
11. Chakravarty K, McDonald H, Pullar T et al. BSR/BHPR guideline for diseasemodifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008;47:924-5.
12. Hirabayashi Y, Shimizu H, Kobayashi N, Kudo K. Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. Intern Med 2006;45:689-91.
13. Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006;36:162-9.
14. Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WA. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 2007;34:1934-7.
15. Ju JH, Kim SI, Lee JH et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007;56:2094-6.
16. Kamata Y, Nara H, Kamimura T et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004;43:1201-4.
17. Ochi S, Harigai M, Mizoguchi F et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol 2006;16:316-20.
18. Otsuka T, Koyama T, Ohtani R et al. Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. Mod Rheumatol 2008;18:96-9.
19. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005;32:1160-3.
20. Vallbracht II, Popper HH, Rieber J et al. Lethal pneumonitis under leflunomide therapy. Rheumatology 2005;44:1580-1.
21. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987; 14:1164-71.
22. Balakrishnan C, Dasgupta B. Pulmonary adverse events with leflunomide-myth or reality? Rheumatology 2007;46:372-3.
23. Sakai F, Noma S, Kurihara Y et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005;15:173-9.
24. Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology 2006;45:787-9.
25. Ito S, Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 2004;43:1103-4.
26. Hider SL, Morgan C, Bell E, Bruce IN. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with RA? Ann Rheum Dis 2003; 62:591-2.
27. van Ede AE, Laan RF, Blom HJ, De Abreu RA, Van De Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
28. Bartram SA. Experience with methotrexate-associated pneumonitis in northeastern England: comment on the article by Kremer et al. Arthritis Rheum 1998;41:1327-8.
29. Kremer JM, Alarcon GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40:1829-37.
30. Weiner RS, Bortin MM, Gale RP et al. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med 1986;104:168-75.
31. Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996;35:441-5.
32. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987;16:186-95.
33. Kremer JM, Alarcon GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
34. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987; 14:1164-71.
35. Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology 2008;47:1647-50.
36. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15mg per week in rheumatoid arthritis. Rheumatol Int 1996;15:195-200.
37. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001;56:622-7.
38. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-9.